RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.
The Manila Times

Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
European Medical Journal

What if Every Patient’s Immune System Could be Guided by the World’s Most Powerful Computers to Fight Cancer? The UK Cancer Vaccines AI and Supercomput…

Cancer evolves through layers of change: mutations in DNA, shifts in gene regulation, altered cell behaviour, and dynamic ...

New research identifies key strategies for global drug safety studies

A new study published in Therapeutic Innovation & Regulatory Science provides crucial insights into the design and ...

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...
eLife

Specialisation of meiotic kinetochores revealed through a synthetic SAC strategy

The authors present convincing data to validate abscisic acid-induced dimerisation to induce a synthetic spindle assembly checkpoint (SAC) arrest that will be of particular importance to analyse ...